Attached files
| file | filename |
|---|---|
| EX-99.2 - EX-99.2 - Zynerba Pharmaceuticals, Inc. | a17-8185_1ex99d2.htm |
| EX-99.1 - EX-99.1 - Zynerba Pharmaceuticals, Inc. | a17-8185_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8–K
CURRENT REPORT
Pursuant to Section 13 OR 15 (d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 13, 2017
ZYNERBA PHARMACEUTICALS, INC.
(Exact Name of Issuer as Specified in Charter)
|
Delaware |
|
001-37526 |
|
26-0389433 |
|
(State or Other Jurisdiction of |
|
(Commission |
|
(I.R.S. Employer |
|
80 W. Lancaster Avenue, Suite 300 Devon, PA 19333 |
|
(Address of Principal Executive Offices) |
(484) 581-7505
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8–K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)
o Pre–commencement communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))
o Pre–commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))
Item 7.01 Regulation FD Disclosure
On March 13, 2017, Zynerba Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it has completed enrollment in the Phase 2 STAR1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in adult epilepsy patients with refractory focal seizures. The Company also announced that enrollment has completed in the Phase 2 STOP (Synthetic Transdermal Cannabidiol for the Treatment of Knee Pain due to Osteoarthritis) clinical trial evaluating ZYN002 CBD gel for the treatment of osteoarthritis. A copy of this press release is attached hereto as Exhibit 99.1.
The information in this Item 7.01 (including Exhibit 99.1) is being furnished solely to satisfy the requirements of Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
Item 8.01 Other Events
Attached as Exhibit 99.2 is a presentation that the Company will post on its website on March 13, 2017 and may use from time to time in presentations or discussions with investors, analysts and other parties.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit |
|
Document |
|
|
|
|
|
99.1 |
|
Press Release, dated March 13, 2017. |
|
|
|
|
|
99.2 |
|
Zynerba Pharmaceuticals, Inc. Presentation. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 13, 2017
|
|
ZYNERBA PHARMACEUTICALS, INC. | |
|
|
| |
|
|
By: |
/s/ Suzanne Hanlon |
|
|
|
Name: Suzanne Hanlon |
|
|
|
Title: Secretary, General Counsel and Vice President, Human Resources |